|1||Not yet recruiting||
A Open-label Extension Study to Assess Long-term Safety of Evolocumab in Subjects Who Completed Fourier (20110118)
Evaluating PCSK9 Binding antiBody Influence oN coGnitive HeAlth in High cardiovascUlar Risk Subjects
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
† Study has passed its completion date and status has not been verified in more than two years.